[Response to the position of the "Biological Psychiatry" Working Group of the Federal Directors Conference--Association of Executive Physicians of Psychiatry and Psychotherapy Clinics (BDK) e.V].
Volkmar
V
Aderhold
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000633:toxicity*; D001921:Brain / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D002423:Cause of Death; D016757:Death, Sudden, Cardiac / Q000453:epidemiology / Q000209:etiology*; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced* / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D006801:Humans; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000401:mortality; D019636:Neurodegenerative Diseases / Q000139:chemically induced* / Q000401:mortality; D017448:Receptors, Dopamine D2 / Q000187:drug effects; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy* / Q000401:mortality; D015854:Up-Regulation / Q000187:drug effects
D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2